Literature DB >> 18443229

Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension.

Edwin K Jackson1, Zaichuan Mi.   

Abstract

Dipeptidyl peptidase IV converts neuropeptide Y(1-36) (Y(1)-receptor agonist released from renal sympathetic nerves) to neuropeptide Y(3-36) (selective Y(2)-receptor agonist). Previous studies suggest that Y(1), but not Y(2), receptors enhance renovascular responses to angiotensin II in kidneys from genetically-susceptible animals. Therefore, we hypothesized that inhibition of dipeptidyl peptidase IV with sitagliptin (antidiabetic drug) would augment the ability of exogenous and endogenous neuropeptide Y(1-36) to enhance renal vascular responses to angiotensin II in kidneys from spontaneously hypertensive rats. This hypothesis was tested using 3 protocols in isolated perfused kidneys. Results from Protocol 1: Exogenous neuropeptide Y(1-36) enhanced renovascular responses to angiotensin II. This effect of neuropeptide Y(1-36) was blocked by BIBP3226 (selective Y(1) receptor antagonist); Exogenous neuropeptide Y(3-36) did not enhance renovascular responses to angiotensin II. Results from Protocol 2: Sitagliptin augmented the ability of exogenous neuropeptide Y(1-36) to enhance renovascular responses to angiotensin II. This effect of sitagliptin was blocked by BIBP3226. Results from Protocol 3: Renal sympathetic nerve stimulation enhanced renovascular responses to angiotensin II; this enhancement was augmented by sitagliptin and abolished by BIBP3226. Neuropeptide Y(1-36) via Y(1) receptors enhances renovascular responses to angiotensin II in kidneys from genetically hypertensive animals. Sitagliptin, by blocking dipeptidyl peptidase IV, prevents metabolism of neuropeptide Y(1-36) and thereby increases the effects of neuropeptide Y(1-36) released from renal sympathetic nerves on Y(1) receptors leading to augmentation of neuropeptide Y(1-36)-induced enhancement of the renovascular effects of angiotensin II. The renal effects of dipeptidyl peptidase IV inhibitors in hypertensive diabetic patients merit a closer examination.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18443229      PMCID: PMC2396195          DOI: 10.1161/HYPERTENSIONAHA.108.112532

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  19 in total

1.  Enhancing release of peptide YY after near-total proctocolectomy: jejunal pouch vs. ileal pouch-distal rectal anastomosis.

Authors:  F V Teixeira; M Pera; K A Kelly
Journal:  J Gastrointest Surg       Date:  2001 Jan-Feb       Impact factor: 3.452

2.  Role of dipeptidyl peptidase IV in regulating activity of Na+/H+ exchanger isoform NHE3 in proximal tubule cells.

Authors:  Adriana C C Girardi; Felix Knauf; Hans-Ulrich Demuth; Peter S Aronson
Journal:  Am J Physiol Cell Physiol       Date:  2004-06-22       Impact factor: 4.249

Review 3.  Neural control of renal function.

Authors:  G F DiBona; U C Kopp
Journal:  Physiol Rev       Date:  1997-01       Impact factor: 37.312

4.  Mechanisms of peptide YY release induced by an intraduodenal meal in rats: neural regulation by proximal gut.

Authors:  X Fu-Cheng; Y Anini; J Chariot; N Castex; J P Galmiche; C Rozé
Journal:  Pflugers Arch       Date:  1997-03       Impact factor: 3.657

Review 5.  Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes.

Authors:  Magnus M Berglund; Philip A Hipskind; Donald R Gehlert
Journal:  Exp Biol Med (Maywood)       Date:  2003-03

6.  Association of Na(+)-H(+) exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule.

Authors:  A C Girardi; B C Degray; T Nagy; D Biemesderfer; P S Aronson
Journal:  J Biol Chem       Date:  2001-10-05       Impact factor: 5.157

7.  alpha 2-Adrenoceptors potentiate angiotensin II- and vasopressin-induced renal vasoconstriction in spontaneously hypertensive rats.

Authors:  Liping Gao; Chongxue Zhu; Edwin K Jackson
Journal:  J Pharmacol Exp Ther       Date:  2003-02-11       Impact factor: 4.030

8.  Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule.

Authors:  Adriana Castello Costa Girardi; Lívia Emy Fukuda; Luciana Venturini Rossoni; Gerhard Malnic; Nancy Amaral Rebouças
Journal:  Am J Physiol Renal Physiol       Date:  2007-12-12

9.  Peptide YY release by fatty acids is sufficient to inhibit gastric emptying in dogs.

Authors:  T N Pappas; H T Debas; A M Chang; I L Taylor
Journal:  Gastroenterology       Date:  1986-12       Impact factor: 22.682

10.  Adaptive increase in peptide YY and enteroglucagon after proctocolectomy and pelvic ileal reservoir construction.

Authors:  D N Armstrong; G H Ballantyne; T E Adrian; A J Bilchik; M A McMillen; I M Modlin
Journal:  Dis Colon Rectum       Date:  1991-02       Impact factor: 4.585

View more
  19 in total

1.  Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.

Authors:  Edwin K Jackson; Zaichuan Mi; Stevan P Tofovic; Delbert G Gillespie
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

2.  Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.

Authors:  Annis Marney; Siri Kunchakarra; Loretta Byrne; Nancy J Brown
Journal:  Hypertension       Date:  2010-08-02       Impact factor: 10.190

3.  Endogenous adenosine contributes to renal sympathetic neurotransmission via postjunctional A1 receptor-mediated coincident signaling.

Authors:  Edwin K Jackson; Dongmei Cheng; Stevan P Tofovic; Zaichuan Mi
Journal:  Am J Physiol Renal Physiol       Date:  2011-11-23

Review 4.  Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system.

Authors:  Annayya R Aroor; James R Sowers; Guanghong Jia; Vincent G DeMarco
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-08-15       Impact factor: 4.733

Review 5.  Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy.

Authors:  Angelo Avogaro; Saula Vigili de Kreutzenberg; Gian Paolo Fadini
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

6.  Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome.

Authors:  David S Tofovic; Victor P Bilan; Edwin K Jackson
Journal:  Clin Exp Pharmacol Physiol       Date:  2010-03-30       Impact factor: 2.557

7.  DPP (Dipeptidyl Peptidase)-4 Inhibition Potentiates the Vasoconstrictor Response to NPY (Neuropeptide Y) in Humans During Renin-Angiotensin-Aldosterone System Inhibition.

Authors:  Scott A Hubers; Jessica R Wilson; Chang Yu; Hui Nian; Eric Grouzmann; Philippe Eugster; Cyndya A Shibao; Frederic T Billings; Scott Jafarian Kerman; Nancy J Brown
Journal:  Hypertension       Date:  2018-09       Impact factor: 10.190

Review 8.  The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors.

Authors:  Angelo Avogaro; Gian Paolo Fadini
Journal:  Br J Clin Pharmacol       Date:  2018-06-03       Impact factor: 4.335

9.  Sitagliptin ameliorates lipid profile changes and endothelium dysfunction induced by atherogenic diet in rabbits.

Authors:  Manar A Nader
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-02-05       Impact factor: 3.000

Review 10.  Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors.

Authors:  Vasiliki Bistola; Vaia Lambadiari; George Dimitriadis; Ioannis Ioannidis; Konstantinos Makrilakis; Nikolaos Tentolouris; Apostolos Tsapas; John Parissis
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.